Predicted to have extracellular matrix structural constituent. Involved in several processes, including animal organ morphogenesis; generation of neurons; and regulation of synapse assembly. Localizes to basement membrane and cytoplasm. Is expressed in several structures, including alimentary system; central nervous system; integumental system; lung; and sensory organ. Human ortholog(s) of this gene implicated in congenital mirror movement disorder. Orthologous to human NTN1 (netrin 1); INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; 4,4'-sulfonyldiphenol; 4-hydroxyphenyl retinamide.
[Tetrachlorodibenzodioxin affects the methylation of NTN1 intron] which results in decreased expression of NTN1 mRNA, Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to NTN1 promoter]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of NTN1 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of NTN1 mRNA
[Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in decreased expression of NTN1 mRNA, Benzoapyrene promotes the reaction [AHR protein binds to NTN1 promoter]
[Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in decreased expression of NTN1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of NTN1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of NTN1 mRNA
[Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in decreased expression of NTN1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of NTN1 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of NTN1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of NTN1 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of NTN1 mRNA
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NTN1 mRNA, [Maneb co-treated with Paraquat] results in decreased expression of NTN1 mRNA
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NTN1 mRNA, [Maneb co-treated with Paraquat] results in decreased expression of NTN1 mRNA
[Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in decreased expression of NTN1 mRNA